Predicting Response to Radical Chemoradiotherapy with Circulating HPV DNA (cHPV-DNA) in Locally Advanced Uterine Cervix Cancer.

Thumbnail Image

Files

Predicting Response to Radical Chemoradiotherapy with Circulating HPV DNA (cHPV-DNA) in Locally Advanced Uterine Cervix Canc.pdf (266.61 KB)

Embargo End Date

ICR Authors

Cutts, Rosalind
 Turner, Nicholas
 Harrington, Kevin
 Bhide, Shreerang

Authors

Lalondrelle, S
Lee, J
Cutts, RJ
Garcia Murillas, I
Matthews, N
Turner, N
Harrington, K
Vroobel, K
Moretti, E
Bhide, SA

Document Type

Journal Article

Date

2023-02-22

Date Accepted

2023-02-21

Abstract

BACKGROUND: The majority of locally advanced cervical cancers (LaCC) are causally related to HPV. We sought to investigate the utility of an ultra-sensitive HPV-DNA next generation sequencing (NGS) assay-panHPV-detect-in LaCC treated with chemoradiotherapy, as a marker of treatment response and persistent disease. METHOD: Serial blood samples were collected from 22 patients with LaCC before, during and after chemoradiation. The presence of circulating HPV-DNA was correlated with clinical and radiological outcomes. RESULTS: The panHPV-detect test demonstrated a sensitivity and specificity of 88% (95% CI-70-99%) and 100% (95% CI-30-100%), respectively, and correctly identified the HPV-subtype (16, 18, 45, 58). After a median follow up of 16 months, and three relapses all had detectable cHPV-DNA at 3 months post-CRT despite complete response on imaging. Another four patients with radiological partial or equivocal response and undetectable cHPV-DNA at the 3-month time point did not go on to develop relapse. All patients with radiological CR and undetectable cHPV-DNA at 3-months remained disease free. CONCLUSIONS: These results demonstrate that the panHPV-detect test shows high sensitivity and specificity for detecting cHPV-DNA in plasma. The test has potential applications in assessment of the response to CRT and in monitoring for relapse, and these initial findings warrant validation in a larger cohort.

Citation

Cancers, 2023, 15 (5), pp. 1387 -

DOI

10.3390/cancers15051387

URI

https://repository.icr.ac.uk/handle/internal/5783

Rights

http://creativecommons.org/licenses/by/4.0/

Source Title

Cancers

Publisher

MDPI

ISSN

2072-6694

eISSN

2072-6694
2072-6694

Collections

Breast Cancer Research

Research Team

Targeted Therapy

Notes